Novo dropped its patent-infringement case against telehealth provider Hims & Hers after the companies agreed that Hims would sell Novo's branded medicines.

On February 17, 2026, BLKBRD Asset Management, LP, disclosed it sold out its entire stake in Hims & Hers Health (HIMS +5.89%), an estimated $18.07 million trade based on quarterly

Hims and Hers (NYSE:HIMS) shares rose 10% Tuesday, adding to Monday’s 49% gain following analyst upgrades after the company announced a collaboration with Novo

Wall Street's major averages ended lower on Friday after nonfarm payrolls unexpectedly contracted in February and oil prices continued to rise. The benchmark S&P 500 closed -1.3%, while the Nasdaq Composite finished -1.

Wondering whether Hims & Hers Health is starting to look attractively priced, or if the market is still getting ahead of itself? This article walks through what the numbers are really saying about its value.